Hyderabad (Telangana) [India], December 28: Hyderabad, Optimus Pharma announced launching of their front line COVID-19 medication Molnupiravir in the Indian market, as they have received permission the restricted emergency use for Covid-19 drug. Optimus Pharma successfully completed the Phase 3 Clinical Trial on 1218 subjects across 29 geographical study sites all over India. “We want to cover maximum demographic diversity into our trial in order to obtain data across the different geographical regions of the country and conclusive evidence that Molnupiravir is able to bring about viral load reduction over 5 days of treatment duration,” said Chairman and Managing Director of Optimus Pharma, Dr D Srinivasa Reddy. Optimus Pharma has developed the API in the house at its R&D centre in Hyderabad. Optimus Pharma has revealed highly promising results of the drug in its ability to reduce viral load and bring out significant symptomatic improvement in patients’ health.
It is to be noted that in the Clinical Trial, Molnupiravir was administered to the subjects along with Standard of Care (SoC) medication as per the approved protocol by CDSCO. The trial was successful in establishing a clinical significant results of ‘Molnupiravir + SoC’ over ‘SoC’ arm.
- Rate of hospitalization was less in Molnupiravir+SoC when compared to SoC group.
- Greater clinical improvement observed in Molnupiravir + SoC arm compared to SOC alone by Day 5 and Day 10.
- Proportion of subjects with RT-PCR negativity at Day 5 and Day 10 was statistically significant in Molnupiravir + SoC arm.
- Higher viral load reduction was observed in Molnupiravir+ SoC arm
- No serious safety concerns observed with Molnupiravir in overall study duration, no mortality was observed in the trial across both the arms
Molnupiravir is administered as an 800 mg dose by orally consuming four capsules of 200mg twice a day. Upon oral administration, Molnupiravir, being a prodrug, is metabolized into its active form and converted into its triphosphate (TP) form. The TP form of Molnupiravir is incorporated into RNA and inhibits the action of viral RNA-dependent RNA polymerase. This results in the termination of RNA transcription, thereby significantly reducing viral replication.
Optimus Pharma is ready with a commercial quantity of the drug to cater to the unmet medical need of the nation. It is with heartfelt gratitude that we thank the Subject Expert Committee of the CDSCO and the DCGI for their valuable recommendations and guidance for the Clinical Trial, thereby making this project a huge success, said Dr D. Srinivas Reddy (MD Optimus) in his statement to the press. Optimus Pharma is committed to consistently integrating quality, affordability and reliability into their products and ensuring timely access to life-saving medication to whomsoever is in need.
The crux of your writing whilst sounding agreeable in the beginning, did not really work well with me after some time. Someplace throughout the paragraphs you managed to make me a believer but only for a very short while. I however have a problem with your leaps in logic and one might do nicely to fill in those breaks. When you can accomplish that, I would surely end up being impressed.
I think that is one of the such a lot significant information for me. And i’m happy reading your article. But want to statement on some general things, The website taste is ideal, the articles is truly great : D. Just right job, cheers
Good write-up, I?¦m normal visitor of one?¦s site, maintain up the nice operate, and It’s going to be a regular visitor for a lengthy time.
I simply couldn’t depart your site prior to suggesting that I really enjoyed the standard information a person supply in your visitors? Is going to be back ceaselessly in order to check out new posts.
As a Newbie, I am continuously searching online for articles that can help me. Thank you
Having read this I thought it was very informative. I appreciate you taking the time and effort to put this article together. I once again find myself spending way to much time both reading and commenting. But so what, it was still worth it!
Thanks for some other informative web site. Where else may just I get that type of information written in such a perfect manner? I have a undertaking that I’m just now operating on, and I have been at the glance out for such information.
Great post. I am facing a couple of these problems.
I do enjoy the manner in which you have presented this specific situation plus it really does give me some fodder for consideration. However, coming from everything that I have experienced, I basically hope when other remarks pile on that folks continue to be on point and don’t embark upon a tirade of some other news of the day. Yet, thank you for this fantastic piece and though I do not necessarily concur with this in totality, I value the standpoint.
I haven?¦t checked in here for a while since I thought it was getting boring, but the last several posts are great quality so I guess I?¦ll add you back to my daily bloglist. You deserve it my friend 🙂
An interesting discussion is worth comment. I think that you should write more on this topic, it might not be a taboo subject but generally people are not enough to speak on such topics. To the next. Cheers
I conceive you have mentioned some very interesting points, regards for the post.
Regards for helping out, excellent info. “Nobody can be exactly like me. Sometimes even I have trouble doing it.” by Tallulah Bankhead.
Great line up. We will be linking to this great article on our site. Keep up the good writing.
Thanks for helping out, good information.
Im not sure the place you’re getting your info, however good topic. I needs to spend a while learning much more or understanding more. Thanks for wonderful info I used to be in search of this information for my mission.